Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Laboratories (formerly Matrix Laboratories) has received tentative FDA approval for abbreviated new drug application (ANDA) for Atorvastatin Calcium Tablets, 10mg (base), 20mg (base), 40mg (base) and 80mg (base).
Subscribe to our email newsletter
Atorvastatin Calcium tablets, generic version of Pfizer’s Lipitor tablets, is indicated for the prevention of cardiovascular disease and hypercholesterolemia.
According to IMS Health, Lipitor had US sales of $8.2bn for the twelve months ending 31 December 2011.
Mylan Laboratories is subsidiary of Mylan, a generic and specialty pharmaceutical company.